Navigation Links
Insulet Reports First Quarter 2008 Results
Date:5/13/2008

let is dependent; Insulet's ability to obtain favorable reimbursement from third-party payors for the OmniPod System and potential adverse changes in reimbursement rates or policies relating to the OmniPod; potential adverse effects resulting from competition with competitors; technological innovations adversely affecting the Company's business; the Company's ability to integrate Dexcom's technology into its product; potential termination of Insulet's license to incorporate a blood glucose meter into the OmniPod System; Insulet's ability to protect its intellectual property and other proprietary rights; conflicts with the intellectual property of third parties; adverse regulatory or legal actions relating to the OmniPod System; the potential violation of federal or state laws prohibiting "kickbacks" and false and fraudulent claims or adverse affects of challenges to or investigations into Insulet's practices under these laws; product liability lawsuits that may be brought against Insulet; unfavorable results of clinical studies relating to the OmniPod System or the products of Insulet's competitors; potential future publication of articles or announcement of positions by physician associations or other organizations that are unfavorable to Insulet's products; Insulet's ability to attract and retain key personnel; Insulet's ability to manage its growth; risks associated with potential future acquisitions; Insulet's ability to maintain compliance with the restrictions and covenants contained in its existing credit and security agreement; Insulet's ability to successfully maintain effective internal controls; and other risks and uncertainties described in the section of its Annual Report on Form 10-K, dated March 18, 2008, which was filed with the Securities and Exchange Commission on March 20, 2008 entitled "Risk Factors" and its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize,
'/>"/>
SOURCE Insulet Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
2. Insulet Corporation to Report Fourth Quarter and Full Year 2007 Financial Results on Monday, March 17
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. QMed, Inc. Reports July Medicare SNP Enrollments
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... 2015  Adaptive Biotechnologies today announced the recent ... The University of Texas MD Anderson Cancer Center ... identification and quantification of populations of B cells ... of people with classical Hodgkin,s lymphoma (CHL). The ... Haematology , represent a first step toward developing ...
(Date:4/28/2015)... ANN ARBOR, Mich. , April 28, 2015 ... OncoTargets and Therapy today shows that the Paradigm ... FoundationOne test across a number of key clinical variables, ... The purpose of the analysis was to ... for profiling cancer patients compared with each other.  ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 More than ... psychosis at some point over the course of their ... symptoms that worsen as the disease progresses. ReachMD ... announces the launch of a series dedicated to PD ... in PD, movement disorders, and psychiatric conditions. , The ...
(Date:4/28/2015)... York, New York (PRWEB) April 28, 2015 ... operations including sales, marketing, and customer service operations across ... The Eeva Test , the first and only FDA-cleared ... proprietary algorithm to aid in embryo selection during IVF. ... career in the field of Reproductive Sciences, including both ...
Breaking Biology Technology:Adaptive Biotechnologies and Researchers from MD Anderson Cancer Center Demonstrate Ability to Detect Hodgkin's Lymphoma in Blood 2Adaptive Biotechnologies and Researchers from MD Anderson Cancer Center Demonstrate Ability to Detect Hodgkin's Lymphoma in Blood 3Paradigm Cancer Diagnostic Test (PCDx) Performed Better Than FoundationOne In Side by Side Clinical Study 2Paradigm Cancer Diagnostic Test (PCDx) Performed Better Than FoundationOne In Side by Side Clinical Study 3ReachMD Launches Series Focusing on Parkinson’s Disease Psychosis 2Progyny Appoints Gary Harton as Group Senior Vice President, Commercial Development 2
... Continues to ... Broaden Product Portfolio, WAYNE, Pa., Feb. 14 ... fiscal second quarter and,six months ended December 31, 2007., For ... the Company,s Drew, Vascular and Escalon Digital Solutions (EMI),business units, which ...
... PALO ALTO, Calif., Feb. 14 CV Therapeutics,Inc. ... accordance with Nasdaq,marketplace rule 4350, the Company issued ... due to additional hiring, primarily in,connection with its ... inducement stock options cover an aggregate 119,200 shares ...
... WASHINGTON, Feb. 14 As part of ... create a pathway for,FDA approval of safe and ... features a footprint in the snow stating: "Don,t ... highlights how meaningful biogenerics legislation should be,balanced to ...
Cached Biology Technology:Escalon(R) Reports Second Quarter Fiscal 2008 Results 2Escalon(R) Reports Second Quarter Fiscal 2008 Results 3Escalon(R) Reports Second Quarter Fiscal 2008 Results 4Escalon(R) Reports Second Quarter Fiscal 2008 Results 5Escalon(R) Reports Second Quarter Fiscal 2008 Results 6Escalon(R) Reports Second Quarter Fiscal 2008 Results 7Escalon(R) Reports Second Quarter Fiscal 2008 Results 8CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 2
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
(Date:3/26/2015)... , March 26, 2015 ... family, social, recreation and athletic club, today announced it ... to allow freedom of movement for members and staff, ... "Following a comprehensive process, we selected FST,s IMID Access ... and convenience for our members and staff, in addition ...
(Date:3/24/2015)... ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition of the ... report to their offering. This report analyzes the worldwide ... following Segments: Face Biometrics, and Voice Biometrics. The report provides separate ... Japan , Europe , ... Africa , and Latin America . ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... by a particular enzyme to modify bacterial chromosome chemistry, ... new kind of drug that could stop virulent bacterial ... in the May 6 issue of the journal Cell. ... enzyme called Dam (DNA adenine methyltransferase) plays a role ...
... that can survive encounters with specific immune system cells ... cells, known as neutrophils, dictate whether our immune system ... the research was released today online in The Journal ... Laboratories (RML), part of the National Institute of Allergy ...
... the field of human embryonic stem cell research receives ... also exploring the potential of adult stem cells for ... adult stem cell research isn't fraught with the controversies ... extremely difficult to isolate and then to multiply in ...
Cached Biology News:Scientists take aim at virulent bacteria by decoding machinery of key control enzyme 2Scientists reveal how disease bacterium survives inside immune system cell 2Scientists reveal how disease bacterium survives inside immune system cell 3Researchers discover mechanism for multiplying adult stem cells 2
Request Info...
Secure-Seal™ spacer, one well, 20 mm diameter, 0.12 mm deep *set of 100*...
Synphilin 1 Immunogen: Synthetic peptide corresponding to residues S(829) L E L N G E K D K D K G R T L Q R T(847) of human Synphilin 1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Request Info...
Biology Products: